Reference: 38 CFR 4.119

Sources & Related Guides

What is the VA rating for Thyroid and Parathyroid Disorders?

Review Thyroid and Parathyroid Disorders guidance covering the RSCH-044-corrected 10-code scope under DC 7900-7919: 6 thyroid codes, 2 neoplasm codes, and 2 parathyroid codes. This is a time-limited-evaluation-then-mandatory-dispatch shape, not a Diabetes-style cumulative ladder.

Condition Overview & Clinical Scope

MOST IMPORTANT TO KNOW FIRST: VA rates thyroid conditions (DC 7900, 7903) and part of hyperparathyroidism (DC 7904) as a TIME-LIMITED evaluation -- a flat percentage for a stated number of months from diagnosis, crisis stabilization, or treatment start -- that then EXPIRES. For DC 7900 (hyperthyroidism) and DC 7903 (hypothyroidism, both tiers), the regulation names NO destination code for what happens after that window ends. Most veterans reaching this hub will already be more than six months past their initial diagnosis -- meaning the single most common real-world scenario in this entire hub is one the regulation itself does not name a rating for. This is disclosed here with the prominence it deserves, not as a routine footnote. VA rates thyroid and parathyroid conditions under 38 CFR 4.119, DC 7900-7919 -- the corrected 3-way scope confirmed in RSCH-044: 6 thyroid codes, 2 neoplasm codes (DC 7914/7915 are endocrine-system-wide malignant/benign neoplasm codes, not thyroid/parathyroid-exclusive -- they also cover pituitary, adrenal, and pancreatic-islet-cell tumors -- included in this hub because VA's combined DBQ documents thyroid and parathyroid neoplasms under these same codes), and 2 parathyroid codes (included because VA's own combined DBQ, Form 21-0960E-3, covers thyroid, parathyroid, and both glands' neoplasms in one instrument).

EXPLORE THIS CONDITION

Explore Thyroid and Parathyroid Disorders Criteria & Tools

Start AssessmentAnswer condition-scoped questions using documented findings from your records or exam notes.ContinuePercentage GuideSee the published percentage tiers and what changes between them.ContinueSecondary ConditionsSee conditions commonly connected to this one in VA claims.Continue

Save this condition to find it again later. Saved only on this device and browser. Never sent to RatingScope. Lost if you clear browser data or switch devices or browsers.

Common Questions & FAQs

Start with your question

What are you trying to understand about thyroid and parathyroid disorders?

Compare your records in assessmentRead overview

Overview

About this condition

MOST IMPORTANT TO KNOW FIRST: VA rates thyroid conditions (DC 7900, 7903) and part of hyperparathyroidism (DC 7904) as a TIME-LIMITED evaluation -- a flat percentage for a stated number of months from diagnosis, crisis stabilization, or treatment start -- that then EXPIRES. For DC 7900 (hyperthyroidism) and DC 7903 (hypothyroidism, both tiers), the regulation names NO destination code for what happens after that window ends. Most veterans reaching this hub will already be more than six months past their initial diagnosis -- meaning the single most common real-world scenario in this entire hub is one the regulation itself does not name a rating for. This is disclosed here with the prominence it deserves, not as a routine footnote. VA rates thyroid and parathyroid conditions under 38 CFR 4.119, DC 7900-7919 -- the corrected 3-way scope confirmed in RSCH-044: 6 thyroid codes, 2 neoplasm codes (DC 7914/7915 are endocrine-system-wide malignant/benign neoplasm codes, not thyroid/parathyroid-exclusive -- they also cover pituitary, adrenal, and pancreatic-islet-cell tumors -- included in this hub because VA's combined DBQ documents thyroid and parathyroid neoplasms under these same codes), and 2 parathyroid codes (included because VA's own combined DBQ, Form 21-0960E-3, covers thyroid, parathyroid, and both glands' neoplasms in one instrument).

Regulatory authority: 38 CFR 4.119, Diagnostic Codes 7900-7919

IMPORTANT DISCLOSURE, READ FIRST: DC 7900's 30 percent tier and DC 7903's 100/30 percent tiers are each time-limited (six months from diagnosis or crisis stabilization) and then expire with NO destination code named in the regulation's own text -- the text simply says to 'rate residuals... within the appropriate diagnostic code(s) within the appropriate body system,' naming nothing specific. This is confirmed as the single most consequential open item in this entire hub, since most real users will already be past this window by the time they use it. RatingScope discloses this honestly rather than guessing a destination or a percentage. This hub explains the published DC 7900-7919 schedule and common record language. It does not diagnose a condition, determine service connection, infer undocumented findings, estimate an outcome, or replace medical care or accredited representation. ADDITIONAL DISCLOSURES: (1) This range is NOT a Diabetes-style cumulative, open-ended treatment-burden ladder -- most codes here are single time-limited evaluations followed by mandatory dispatch, a fundamentally different shape from Diabetes' DC 7913. (2) DC 7903's 100 percent tier (myxedema) has a genuine, unresolved disagreement between the regulation's own criterion text (a chronic manifestation list: cold intolerance, cardiovascular involvement, mental disturbance) and its crisis-stabilization Note plus VA's own DBQ, both of which read this tier acutely ('rare, life-threatening... requires hospitalization'). RatingScope discloses this conflict rather than picking one reading. (3) DC 7901 and DC 7902 (toxic and nontoxic goiter) have NO independent percentage of their own at all -- both are pure redirects. (4) DC 7904 (hyperparathyroidism) is not a uniform exception to the time-limited pattern -- its 60 percent hypercalcemia tier ALSO expires (six months after non-surgical pharmacologic treatment begins) into the same unnamed dispatch, a second, nested instance of this hub's core structural shape. (5) DC 7919's binary dispatch (antineoplastic therapy, or prophylactic thyroidectomy) names no default for a documented 'watchful waiting' state meeting neither branch -- disclosed, not resolved either direction.

Percentage Guides

Understanding Your Percentage

Select a pathway to see what the published criteria ask about, what records may clarify it, and what should not be assumed.

30% (DC 7900, hyperthyroidism, within six months)

Highest listed pathway

Hyperthyroidism (including Graves' disease), for the six months following initial diagnosis.

What separates the next level: After six months, this tier expires. The regulation's own text directs rating residuals in the appropriate body system, but names no destination code -- see the dedicated disclosure on this gap.

Review CFR criteria, examples, and evidence
Official CFR language
7900 Hyperthyroidism, including but not limited to Graves' disease: For six months after initial diagnosis -- 30.
Qualification explanation
DC 7900's single named tier, reached automatically once the diagnosis is confirmed and the six-month window has not yet passed.
Examples
Records document a hyperthyroidism diagnosis confirmed 3 months ago.
Medical evidence
Thyroid and Parathyroid Conditions DBQ; Records establishing the initial diagnosis date
Functional impact examples
Recently diagnosed hyperthyroidism, still within the initial evaluation window.
Common misconceptions
This tier does not continue indefinitely, and there is no explicit lower tier to fall back to -- once it expires, the regulation is silent on what comes next.
Related topics
expiration-gap
Source context
38 CFR 4.119; 7900; Current DC 7900-7919 educational pathway. RIN 2900-AQ72/AQ73/AQ82 do not touch 38 CFR 4.119 (RSCH-044).

100% (DC 7903, hypothyroidism with myxedema)

Highest listed pathway

Hypothyroidism manifesting as myxedema (cold intolerance, muscular weakness, cardiovascular involvement, mental disturbance), for six months beyond crisis stabilization.

What separates the next level: Without myxedema, DC 7903's 30 percent tier applies instead, on its own separate six-month clock from initial diagnosis.

Review CFR criteria, examples, and evidence
Official CFR language
Hypothyroidism manifesting as myxedema... This evaluation shall continue for six months beyond the date that an examining physician has determined crisis stabilization -- 100.
Qualification explanation
Reached once myxedema is documented and the six-month post-stabilization window has not yet passed.
Examples
Records document myxedema-manifesting hypothyroidism, with crisis stabilization confirmed 2 months ago.
Medical evidence
Thyroid and Parathyroid Conditions DBQ; Records establishing crisis stabilization date and myxedema manifestations
Functional impact examples
Severe hypothyroidism with myxedema, within the post-stabilization evaluation window.
Common misconceptions
This tier's criteria are genuinely disputed -- see the dedicated disclosure on the acute-vs-chronic disagreement between the regulation and VA's own DBQ.
Related topics
7903-acute-vs-chronic; expiration-gap
Source context
38 CFR 4.119; 7903; Current DC 7903 educational pathway.

100% (DC 7904, hyperparathyroidism, post-surgery)

Highest listed pathway

Hyperparathyroidism, for the six months from the date of hospital discharge following surgery.

What separates the next level: After this window, DC 7904 continues with a real, mostly-stable 60/10/0 percent ladder -- but the 60 percent hypercalcemia tier itself has a second, hidden six-month clock when treated non-surgically. See its dedicated disclosure.

Review CFR criteria, examples, and evidence
Official CFR language
7904 Hyperparathyroidism: For six months from date of discharge following surgery -- 100.
Qualification explanation
Reached automatically for six months from the date of hospital discharge following surgery.
Examples
Records document hyperparathyroidism surgery, with hospital discharge 3 months ago.
Medical evidence
Thyroid and Parathyroid Conditions DBQ; Surgical records
Functional impact examples
Recent parathyroid surgery, within the post-operative evaluation window.
Common misconceptions
Unlike DC 7900/DC 7903, DC 7904's 10 and 0 percent tiers are genuinely stable, non-expiring findings -- only its 100 and (conditionally) 60 percent tiers are time-limited.
Related topics
7904-nested-expiration
Source context
38 CFR 4.119; 7904; Current DC 7904 educational pathway.

0% (DC 7904/7906, real explicit tiers)

Next: 30%/100% (varies by code and manifestation)

Asymptomatic hyperparathyroidism (DC 7904), or thyroiditis with normal thyroid function (DC 7906), are both genuine, explicitly stated 0 percent outcomes.

What separates the next level: These 0 percent tiers are genuinely stable -- distinct from DC 7900/7903's expired-with-no-named-destination situation, which is NOT a 0 percent outcome, just an undefined one.

Review CFR criteria, examples, and evidence
Official CFR language
7904: 'Asymptomatic -- 0.' 7906: 'With normal thyroid function -- 0.'
Qualification explanation
These are real, stated regulatory outcomes for a documented asymptomatic or normally-functioning presentation.
Examples
Records document thyroiditis with normal, unaffected thyroid function on lab testing.
Medical evidence
Thyroid and Parathyroid Conditions DBQ
Functional impact examples
Findings within the code's own explicitly stated non-compensable range.
Common misconceptions
A 0 percent result here means the regulation directly and explicitly states 0 percent for this finding -- it is not the same as the expired, undefined situation under DC 7900/7903.
Related topics
expiration-gap
Source context
38 CFR 4.119; 7904/7906; Current DC 7900-7919 educational pathway.

100% (DC 7914, malignant neoplasm, any specified part of the endocrine system)

Highest listed pathway

Malignant neoplasm (cancer) of any part of the endocrine system -- not limited to thyroid or parathyroid, this code also covers pituitary, adrenal, and pancreatic-islet-cell cancers, among other endocrine sites -- rated 100 percent through active treatment.

What separates the next level: This 100 percent rating continues beyond the cessation of treatment. Six months after treatment ends, a mandatory VA examination determines the appropriate rating going forward; if there has been no local recurrence or metastasis, VA then rates on residuals under the appropriate diagnostic code(s) instead. DC 7914 is not thyroid/parathyroid-exclusive -- it covers a malignant neoplasm in any specified part of the endocrine system, including pituitary, adrenal, and pancreatic-islet-cell cancers -- it is included in this hub because VA's combined DBQ documents thyroid and parathyroid malignancies under this same code.

Review CFR criteria, examples, and evidence
Official CFR language
7914 Neoplasm, malignant, any specified part of the endocrine system -- 100.
Qualification explanation
Reached automatically once a malignant endocrine-system neoplasm is diagnosed, and continues through active treatment (surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure).
Examples
Records document a malignant thyroid neoplasm currently undergoing antineoplastic chemotherapy.
Medical evidence
Thyroid and Parathyroid Conditions DBQ; Oncology and treatment records; Mandatory VA examination findings six months after treatment ends
Functional impact examples
Active treatment for a malignant endocrine-system neoplasm, or within six months of treatment ending, pending the mandatory VA reexamination.
Common misconceptions
This code is not exclusive to thyroid or parathyroid cancer -- it covers a malignant neoplasm in any specified part of the endocrine system. The 100 percent rating also does not end automatically at six months post-treatment; it continues until the mandatory VA examination determines there is no local recurrence or metastasis, at which point the rating shifts to residuals.
Source context
38 CFR 4.119; 7914; Current DC 7914 educational pathway.

Rate as residuals (DC 7915, benign neoplasm, any specified part of the endocrine system)

Next: Varies -- determined by the diagnostic code covering the specific resulting endocrine dysfunction, if any

Benign neoplasm of any part of the endocrine system -- like DC 7914, not limited to thyroid or parathyroid -- has no independent percentage of its own; VA rates it based on whatever residual endocrine dysfunction it actually causes.

What separates the next level: Unlike DC 7914's malignant-neoplasm code, DC 7915 has no percentage tiers of its own at all -- structurally similar to DC 7901/DC 7902's pure redirects, but for benign growths anywhere in the endocrine system rather than goiter specifically. DC 7915 is not thyroid/parathyroid-exclusive -- it covers a benign neoplasm in any specified part of the endocrine system, including pituitary, adrenal, and pancreatic-islet-cell growths -- it is included in this hub because VA's combined DBQ documents thyroid and parathyroid benign neoplasms under this same code.

Review CFR criteria, examples, and evidence
Official CFR language
7915 Neoplasm, benign, any specified part of the endocrine system: Rate as residuals of endocrine dysfunction.
Qualification explanation
Applies once a benign endocrine-system neoplasm is diagnosed. DC 7915 does not assign its own percentage -- VA instead rates whatever endocrine dysfunction the growth actually causes under the appropriate diagnostic code(s).
Examples
Records document a benign thyroid neoplasm with no resulting hormonal dysfunction documented.
Medical evidence
Thyroid and Parathyroid Conditions DBQ; Pathology records confirming benign status; Records documenting any resulting endocrine dysfunction
Functional impact examples
A diagnosed benign endocrine-system neoplasm, with the actual rating determined by whatever residual dysfunction, if any, it causes.
Common misconceptions
This code is not exclusive to thyroid or parathyroid growths -- it covers a benign neoplasm in any specified part of the endocrine system. It also carries no percentage of its own -- a 0 percent-equivalent result requires no documented resulting dysfunction, not simply a benign diagnosis.
Source context
38 CFR 4.119; 7915; Current DC 7915 educational pathway.

Learn

Understand the details behind the criteria

Use these short guides to connect published terms with the records and observations that may clarify them.

The six-month clock and its unnamed destination (read this first)

DC 7900's 30 percent tier and both of DC 7903's tiers are time-limited to six months from diagnosis or crisis stabilization. After that window, the regulation's own text says to 'rate residuals of disease or complications of medical treatment within the appropriate diagnostic code(s) within the appropriate body system' -- naming NO specific destination code.

  • This is confirmed, via fresh verbatim fetch cross-checked against two independent primary sources, as the single most consequential open item in this entire hub -- because most veterans using this hub will already be more than six months past their initial thyroid diagnosis, this undefined-destination scenario is not an edge case, it is the majority scenario.
  • RatingScope discloses this honestly: past the six-month window, this hub returns a 'needs review' result explaining that no destination code is named, rather than guessing a body system or a percentage.
  • DC 7905 (hypoparathyroidism) has a similar three-month window, but its post-expiration text is somewhat more specific -- it names residual CATEGORIES (kidney stones, cataracts, decreased renal function, congestive heart failure), just not specific diagnostic code numbers.

Records to review: Records establishing the initial diagnosis date or crisis-stabilization date.

Why this hub is not modeled like Diabetes

Diabetes (DC 7913) is a cumulative, open-ended treatment-burden ladder -- the more treatment required, the higher the tier, indefinitely. Most of this hub's codes are the opposite: a single flat percentage for a STATED, LIMITED number of months, after which the tier itself ends.

  • This structural difference was confirmed and flagged during this hub's research phase specifically so it would not be built using the wrong precedent.
  • DC 7904 (hyperparathyroidism) is the closest thing to a genuine multi-tier ladder in this range, but even it has a hidden time-limited element in its 60 percent tier -- see its own dedicated disclosure.
  • Only DC 7904's 10 and 0 percent tiers, and DC 7906's 0 percent tier, are genuinely stable, non-expiring findings the way Diabetes' tiers are.

Records to review: Treatment records documenting the diagnosis timeline.

DC 7903's 100 percent tier: a real disagreement between the regulation and VA's own DBQ

DC 7903's 100 percent criterion text itself reads as a chronic manifestation list (cold intolerance, cardiovascular involvement, mental disturbance), while its own crisis-stabilization Note, and VA's current Thyroid and Parathyroid Conditions DBQ, both read this tier acutely -- as a rare, life-threatening myxedema crisis requiring hospitalization.

  • This is a genuine disagreement between the source hierarchy's two levels (the regulation itself, and VA's implementing examination instrument) that cannot be resolved by RatingScope's own established rule that the eCFR governs and the DBQ never overrides -- because the eCFR's own text is internally ambiguous here, not simply overridden by the DBQ.
  • RatingScope discloses this conflict rather than guessing which reading -- chronic manifestation list, or acute crisis -- the regulation actually intends.

Records to review: Thyroid and Parathyroid Conditions DBQ; Hospitalization records, if applicable.

DC 7901 and DC 7902: no percentage of their own

Toxic goiter (DC 7901) and nontoxic goiter (DC 7902) have NO independent rating percentage at all -- both codes' entire text is a redirect.

  • DC 7901 directs evaluating hyperthyroidism symptoms under DC 7900 -- RatingScope's own hub already covers that pathway directly.
  • DC 7902 directs evaluating pressure symptoms on the trachea, larynx, or esophagus under the appropriate body-system code, with none named.
  • Both codes separately direct rating any neck disfigurement under DC 7800 (Scars) -- disclosed here as a cross-reference to review separately, never auto-computed into the Scars hub's own facts.

Records to review: Thyroid and Parathyroid Conditions DBQ; Examination records documenting any pressure symptoms or neck disfigurement.

DC 7904's own hidden six-month clock

Hyperparathyroidism's 60 percent hypercalcemia tier is not a permanent ladder rung -- when treated non-surgically, it continues for only six months after pharmacologic treatment begins, then expires into the same unnamed residual dispatch found elsewhere in this hub.

  • This is a second, nested instance of the range's core time-limited-then-dispatch structural shape, confirmed via fresh verbatim fetch -- not obvious from a first read of DC 7904's tier list, which can look like a stable, permanent ladder.
  • This expiration only applies when surgical intervention is NOT indicated -- surgically-treated hyperparathyroidism's own 100 percent tier has its own separate six-month post-surgery window instead.
  • DC 7904's 10 percent (persistent symptoms/continuous medication) and 0 percent (asymptomatic) tiers are genuinely stable and do not expire.

Records to review: Records documenting whether treatment is surgical or pharmacologic, and the treatment start date.

Evidence

Evidence that may clarify the published criteria

Records establishing the initial diagnosis, crisis-stabilization, or date of discharge following surgery

Establishes where a veteran falls on this hub's time-limited evaluation windows (six months for DC 7900/7903/7904's post-surgery tier and non-surgical 60 percent tier, three months for DC 7905) -- the single most load-bearing fact type in this hub.

Not required for DC 7904's genuinely stable 10/0 percent tiers, or DC 7906's 0 percent tier.

Documented myxedema manifestations or hypercalcemia lab/imaging values

The specific clinical findings distinguishing DC 7903's two tiers and DC 7904's hypercalcemia tier.

Only relevant to hypothyroidism or hyperparathyroidism diagnoses.

Thyroid and Parathyroid Conditions Disability Benefits Questionnaire

VA's combined examination form covering thyroid, parathyroid, and both glands' neoplasms in one instrument -- the reason parathyroid conditions are included in this hub's scope.

A DBQ is one common evidence source, not the only way to document these findings.

Official VA Forms & DBQs

Downloadable DBQs & Supporting Claim Forms

Take the public DBQ to your private physician or review it prior to your C&P examination.

Terminology

Plain-English terms

Myxedema

The most severe stage of underactive thyroid disease -- though the regulation and VA's own exam form describe it two different ways.

Determines whether DC 7903's 100 percent or 30 percent tier applies.

Thyroid and Parathyroid Conditions DBQ; 7903-acute-vs-chronic

Back to rating criteriaCompare your records

Rate on residuals

Once the initial evaluation period ends, VA looks at what lasting problems remain and rates those specifically.

Used by DC 7900, DC 7903 (both tiers), DC 7904's 60 percent tier, and DC 7905 -- several of these name no specific destination code at all.

Treatment records confirming the applicable window has ended; expiration-gap

Back to rating criteriaCompare your records

TDIU

Even if the schedular rating for Thyroid and Parathyroid Disorders does not reach 100 percent, TDIU may still provide a pathway to compensation at the 100 percent rate, based on unemployability from this and/or other service-connected disabilities combined.

A lower schedular percentage does not by itself foreclose TDIU eligibility -- this hub computes only the schedular percentage for this specific condition and does not determine TDIU eligibility.

Employment history; vocational impact documentation; occupational impairment

Back to rating criteriaCompare your records

Common Questions

Questions veterans commonly ask

What happens after six months?

For DC 7900 (hyperthyroidism) and DC 7903 (hypothyroidism, both tiers), the regulation names NO specific destination code -- it simply says to rate residuals in the appropriate body system. This is the single most consequential open item in this hub, since most veterans using it will already be past this window.

How does VA rate hyperthyroidism or hypothyroidism?

Both are time-limited evaluations: DC 7900 (hyperthyroidism) is a flat 30 percent for six months from diagnosis. DC 7903 (hypothyroidism) is 100 percent (with myxedema) or 30 percent (without), each on its own six-month clock. Both expire with no destination code named.

Is this hub structured like the Diabetes hub?

No. Diabetes is a cumulative, open-ended treatment-burden ladder. Most of this hub's codes are single, time-limited evaluations that expire into a residual dispatch -- a fundamentally different shape, confirmed and flagged specifically so this hub would not be built using the wrong precedent.

Is DC 7903's 100 percent tier for a chronic condition or an acute crisis?

Genuinely unclear. The regulation's own criterion text reads as a chronic manifestation list, while its crisis-stabilization Note and VA's own DBQ both read it as an acute, life-threatening crisis. RatingScope discloses this disagreement rather than picking one reading.

What about toxic or nontoxic goiter?

Neither has any rating percentage of its own. Toxic goiter (DC 7901) redirects to DC 7900 (hyperthyroidism). Nontoxic goiter (DC 7902) redirects pressure symptoms to an unnamed body-system code. Both separately redirect any neck disfigurement to DC 7800 (Scars).

Does hyperparathyroidism also have an expiration gap?

Partially. Its 60 percent hypercalcemia tier expires (six months after non-surgical treatment begins) into the same unnamed dispatch found elsewhere in this hub. Its 10 and 0 percent tiers, however, are genuinely stable and do not expire.

If my schedular rating for Thyroid and Parathyroid Disorders is below 100%, can I still be compensated at the 100% rate?

Possibly, through TDIU (Total Disability rating based on Individual Unemployability, 38 CFR 4.16) -- a separate pathway to 100 percent compensation based on unemployability, from this and/or other service-connected disabilities combined, independent of whether the schedular rating itself reaches 100 percent. This hub computes only the schedular percentage and does not determine TDIU eligibility.

What separates the 30% (DC 7900, hyperthyroidism, within six months) rating from adjacent levels?

After six months, this tier expires. The regulation's own text directs rating residuals in the appropriate body system, but names no destination code -- see the dedicated disclosure on this gap.

What separates the 100% (DC 7903, hypothyroidism with myxedema) rating from adjacent levels?

Without myxedema, DC 7903's 30 percent tier applies instead, on its own separate six-month clock from initial diagnosis.

What separates the 100% (DC 7904, hyperparathyroidism, post-surgery) rating from adjacent levels?

After this window, DC 7904 continues with a real, mostly-stable 60/10/0 percent ladder -- but the 60 percent hypercalcemia tier itself has a second, hidden six-month clock when treated non-surgically. See its dedicated disclosure.

What separates the 0% (DC 7904/7906, real explicit tiers) rating from adjacent levels?

These 0 percent tiers are genuinely stable -- distinct from DC 7900/7903's expired-with-no-named-destination situation, which is NOT a 0 percent outcome, just an undefined one.

What separates the 100% (DC 7914, malignant neoplasm, any specified part of the endocrine system) rating from adjacent levels?

This 100 percent rating continues beyond the cessation of treatment. Six months after treatment ends, a mandatory VA examination determines the appropriate rating going forward; if there has been no local recurrence or metastasis, VA then rates on residuals under the appropriate diagnostic code(s) instead. DC 7914 is not thyroid/parathyroid-exclusive -- it covers a malignant neoplasm in any specified part of the endocrine system, including pituitary, adrenal, and pancreatic-islet-cell cancers -- it is included in this hub because VA's combined DBQ documents thyroid and parathyroid malignancies under this same code.

What separates the Rate as residuals (DC 7915, benign neoplasm, any specified part of the endocrine system) rating from adjacent levels?

Unlike DC 7914's malignant-neoplasm code, DC 7915 has no percentage tiers of its own at all -- structurally similar to DC 7901/DC 7902's pure redirects, but for benign growths anywhere in the endocrine system rather than goiter specifically. DC 7915 is not thyroid/parathyroid-exclusive -- it covers a benign neoplasm in any specified part of the endocrine system, including pituitary, adrenal, and pancreatic-islet-cell growths -- it is included in this hub because VA's combined DBQ documents thyroid and parathyroid benign neoplasms under this same code.

Related Conditions

Continue learning through connected topics

Scars

DC 7901 and DC 7902 both separately direct rating any neck disfigurement under DC 7800 (Scars).

Heart Conditions

DC 7900's own Note directs separately rating hyperthyroid heart disease under DC 7008.

Eye Conditions

DC 7900 and DC 7903 both direct separately rating eye involvement (diplopia, visual acuity impairment, exophthalmos).

Ready when you are

Compare documented thyroid and parathyroid condition findings

Use the diagnosis, diagnosis date, and lab-value language already documented in your records. Do not upload records or enter Social Security numbers, claim numbers, full dates of birth, or other sensitive identifiers. RatingScope does not infer missing findings.

Informational guidance only. RatingScope does not predict, decide, or guarantee VA outcomes.

Compare my thyroid or parathyroid condition records

Learn More

Continue Understanding

Secondary conditions

Conditions commonly connected to Thyroid and Parathyroid Disorders

No commonly documented secondary connections are tracked for Thyroid and Parathyroid Disorders yet.

Keep going

Related Tools

Compare a percentage level and combined-rating math, or review evidence context.

See all tools

VA Math & Combined Ratings

Understand the whole-person method, final rounding, and bilateral limits, then calculate how percentages combine.

Open VA Math guide

Evidence Center

Understand common evidence categories and what they can clarify without treating them as a checklist.

Open Evidence Center